BioRestorative Therapies, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BRTX Nasdaq 2836 www.biorestorative.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioRestorative Therapies, Inc.

Breakeven On The Horizon For BioRestorative Therapies, Inc. (NASDAQ:BRTX) - Jul 15th, 2025 5:05 am
BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates - Jun 18th, 2025 7:35 am
BioRestorative Announces Share Repurchase Program - Jun 17th, 2025 7:25 am
BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease - Jun 13th, 2025 5:45 am
BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team - Jun 10th, 2025 6:00 am
BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025 - Jun 9th, 2025 5:45 am
BioRestorative Therapies Inc (BRTX) Q1 2025 Earnings Call Highlights: Navigating Challenges ... - May 15th, 2025 1:17 am
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Lags Revenue Estimates - May 14th, 2025 4:35 pm
BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update - May 14th, 2025 2:05 pm
Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data - May 13th, 2025 7:15 am
BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025 - May 8th, 2025 2:30 pm
BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025 - May 7th, 2025 7:15 am
BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities - Apr 15th, 2025 6:30 am
BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States - Apr 10th, 2025 7:15 am
BioRestorative Therapies Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Mar 29th, 2025 7:24 am
BioRestorative Therapies Reports 2024 Financial Results and Provides Business Update - Mar 27th, 2025 2:05 pm
BioRestorative Therapies to Report 2024 Financial Results and Host Conference Call on March 27, 2025 - Mar 20th, 2025 2:30 pm
BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain - Feb 27th, 2025 7:45 am
BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update - Feb 26th, 2025 6:15 pm
BioRestorative to Provide a Positive FDA Update on Clinical Pipeline - Feb 25th, 2025 6:00 am